Previous 10 | Next 10 |
home / stock / lly / lly articles
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 20 years by 4.84% on an annualized basis producing an average annual return o...
Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization...
As the weight-loss frenzy fueled by social media endorsements and Hollywood glamour continues to surge, the battle against counterfeit medicat...
U.S. stocks experienced a rise on Tuesday following consecutive losses for the S&P 500 and Nasdaq. What Happened: This positive turn occurred d...
Monday, AnaptysBio Inc (NASDAQ:ANAB) reported a fourth-quarter 2023 EPS of $(1.59), slightly better than the consensus of $(1.60). T...
Future Fund co-founder Gary Black on Monday shared information about legendary television mogul Oprah Winfrey’s upcoming TV sp...
In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess comp...
The FDA expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to discuss Eli Lilly and Company...
Retail traders have been observed to be selling off their shares in the ‘Magnificent Seven’ tech stocks, with a noticeable shift toward...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...